A phase Ib, multicenter, open-label study of the antibody-drug conjugate trastuzumab deruxtecan (DS-8201a) combination with nivolumab for advanced HER2-expressing breast or urothelial cancer

被引：0
|
作者：
Hurvitz, S. A. [1 ]
Galsky, M. D. [2 ]
Shahidi, J. [3 ]
Zhang, G. [4 ]
Raza, S. [3 ]
Necchi, A. [5 ]
机构：
[1] UCLA Med Ctr, Dept Med, Los Angeles, CA USA
[2] Icahn Sch Med Mt Sinai, Dept Med, New York, NY 10029 USA
[3] Daiichi Sankyo Inc, Clin Dev, Basking Ridge, NJ USA
[4] Daiichi Sankyo Inc, Biostat & Data Management, Basking Ridge, NJ USA
[5] Fdn IRCCS Ist Nazl Tumori, Med Oncol, Milan, Italy
来源：
ANNALS OF ONCOLOGY | 2018年 / 29卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
370TiP
引用
收藏
页数：1
相关论文
共 50 条
  • [1] A randomized, phase II, multicenter, open-label study of trastuzumab deruxtecan (DS-8201a) in subjects with HER2-expressing gastric cancer
    Shitara, K.
    Bang, Y-J.
    Sakai, D.
    Yasui, H.
    Kawaguchi, Y.
    Sugihara, M.
    Saito, K.
    Dalal, R.
    Yamaguchi, K.
    ANNALS OF ONCOLOGY, 2018, 29 : 65 - 65
  • [2] A randomized phase 2, multicenter, open-label study of trastuzumab deruxtecan (DS-8201a) in subjects with HER2-expressing gastric cancer.
    Yamaguchi, Kensei
    Bang, Yung-Jue
    Sakai, Daisuke
    Yasui, Hisateru
    Kawaguchi, Yoshinori
    Sugihara, Masahiro
    Saito, Kaku
    Dalal, Rita
    Shitara, Kohei
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [3] Trastuzumab Deruxtecan with Nivolumab in HER2-Expressing Metastatic Breast or Urothelial Cancer: Analysis of the Phase Ib DS8201-A-U105 Study
    Hamilton, Erika
    Galsky, Matthew D.
    Ochsenreither, Sebastian
    Del Conte, Gianluca
    Martin, Miguel
    De Miguel, Maria Jose
    Yu, Evan Y.
    Williams, Anja
    Gion, Maria
    Tan, Antoinette R.
    Agrawal, Laila
    Rutten, Annemie
    Machiels, Jean-Pascal
    Cresta, Sara
    Debruyne, Philip R.
    Hennequin, Audrey
    Moreno, Victor
    Minchom, Anna
    Valdes-Albini, Frances
    Petrylak, Daniel
    Li, Li
    Tsuchihashi, Zenta
    Suto, Fumitaka
    Cheng, Fu-Chih
    Kandil, Maha
    Barrios, Daniel
    Hurvitz, Sara
    CLINICAL CANCER RESEARCH, 2024, 30 (24) : 5548 - 5558
  • [4] Updated results of phase I study of trastuzumab deruxtecan (DS-8201a) in HER2-expressing advanced colorectal cancer
    Yoshino, T.
    Iwata, H.
    Tamura, K.
    Takahashi, S.
    Redfern, C.
    Modi, S.
    Doi, T.
    Kawakami, H.
    Taniguchi, H.
    Takashima, A.
    Yamaguchi, K.
    Fisher, J.
    Li, B.
    Saito, K.
    Fujisaki, Y.
    Sugihara, M.
    Tsurutani, J.
    ANNALS OF ONCOLOGY, 2018, 29
  • [5] A multicenter, multicohort, phase II study of trastuzumab deruxtecan (DS-8201a) in subjects with HER2-expressing metastatic colorectal cancer
    Yoshino, T.
    Siena, S.
    Dalal, R.
    Okuda, Y.
    Yamamoto, E.
    Grothey, A.
    ANNALS OF ONCOLOGY, 2018, 29 : 45 - 45
  • [6] Trastuzumab deruxtecan (T-DXd; DS-8201) with nivolumab in patients with HER2-expressing, advanced breast cancer: A 2-part, phase 1b, multicenter, open-label study
    Hamilton, Erika
    Shapiro, Charles L.
    Petrylak, Daniel
    Boni, Valentina
    Martin, Miguel
    Del Conte, Gianluca
    Cortes, Javier
    Agarwal, Laila
    Arkenau, Hendrik-Tobias
    Tan, Antoinette R.
    Debruyne, Philip
    Minchom, Anna
    Rutten, Annemie
    Valdes-Albini, Frances
    Yu, Evan Y.
    Augustine, Bincy
    D'Amelio, Anthony, Jr.
    Barrios, Daniel
    Hurvitz, Sara A.
    CANCER RESEARCH, 2021, 81 (04)
  • [7] A phase II, multicenter, open-label study of [fam-] trastuzumab deruxtecan (DS 8201a) in subjects with HER2-expressing gastric cancer.
    Shitara, Kohei
    Bang, Yung-Jue
    Chung, Hyun Cheol
    Yabusaki, Hiroshi
    Iwasa, Satoru
    Sakai, Daisuke
    Muro, Kei
    Sugimoto, Naotoshi
    Yasui, Hisateru
    Gamoh, Makio
    Murakawa, Yasuko
    Negoro, Yuji
    Nishina, Tomohiro
    Hosaka, Hisashi
    Omuro, Yasushi
    Kawaguchi, Yoshinori
    Sugihara, Masahiro
    Saito, Kaku
    Dalal, Rita
    Yamaguchi, Kensei
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (04)
  • [8] A multicenter, multicohort, phase 2 study of trastuzumab deruxtecan (DS-8201a) in subjects with HER2-expressing metastatic colorectal cancer - Trial in progress
    Yoshino, T.
    Siena, S.
    Dalal, R.
    Okuda, Y.
    Yamamoto, E.
    Grothey, A.
    ANNALS OF ONCOLOGY, 2018, 29
  • [9] A phase 1, multicenter, open-label study to assess the effect of [fam-] trastuzumab deruxtecan (T-DXd; DS-8201a) on QTc and pharmacokinetics in subjects with HER2-expressing metastatic and/or unresectable breast cancer
    Yamashita, Toshinari
    Shimomura, Akihiko
    Takano, Toshimi
    Sagara, Yasuaki
    Watanabe, Junichiro
    Tokunaga, Eriko
    Kikumori, Kunika
    Kamiyama, Emi
    Kamio, Takahiro
    Nakamura, Ryo
    Shinkai, Tetsu
    Takahashi, Shunji
    CANCER RESEARCH, 2020, 80 (04)
  • [10] The Latest Research and Development into the Antibody-Drug Conjugate, [fam-] Trastuzumab Deruxtecan (DS-8201a), for HER2 Cancer Therapy
    Nakada, Takashi
    Sugihara, Kiyoshi
    Jikoh, Takahiro
    Abe, Yuki
    Agatsuma, Toshinori
    CHEMICAL & PHARMACEUTICAL BULLETIN, 2019, 67 (03) : 173 - 185
12345